Zoetis (ZTS) Shares Outstanding (Weighted Average) (2012 - 2026)
Zoetis (ZTS) reported Shares Outstanding (Weighted Average) of $422.1 million for Q1 2026, down 5.7% year-over-year from $447.6 million in Q1 2025, and down 4.81% quarter-over-quarter from $443.4 million in Q4 2025.
Zoetis (ZTS) Shares Outstanding (Weighted Average) (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Shares Outstanding (Weighted Average) data on file, last reported at $422.1 million in Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $422.1 million, down 5.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $422.1 million (down 5.7% YoY), and the FY2025 annual result was $443.4 million, down 2.37% from the prior year.
- Shares Outstanding (Weighted Average) fell to $422.1 million in Q1 2026 per ZTS's latest filing, from $443.4 million in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $472.2 million in Q1 2022 and troughed at $422.1 million in Q1 2026.
- A 5-year average of $456.4 million and a median of $458.0 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Weighted Average) retreated 0.69% in 2022, then slipped 5.7% in 2026.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $468.9 million in 2022, then retreated by 1.65% to $461.2 million in 2023, then fell by 1.51% to $454.2 million in 2024, then decreased by 2.37% to $443.4 million in 2025, then fell by 4.81% to $422.1 million in 2026.
- Business Quant data shows ZTS's Shares Outstanding (Weighted Average) at $422.1 million in Q1 2026, $443.4 million in Q4 2025, and $445.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 1.16 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 422.10 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 43.50 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 5.02 Bn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 100.50 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 497.70 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 166.20 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 64.74 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 228.36 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 88.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 422.10 Mn |
| Dec 31, 2025 | 443.44 Mn |
| Sep 30, 2025 | 445.20 Mn |
| Jun 30, 2025 | 446.30 Mn |
| Mar 31, 2025 | 447.60 Mn |
| Dec 31, 2024 | 454.20 Mn |
| Sep 30, 2024 | 455.40 Mn |
| Jun 30, 2024 | 456.70 Mn |
| Mar 31, 2024 | 458.00 Mn |
| Dec 31, 2023 | 461.17 Mn |
| Sep 30, 2023 | 460.30 Mn |
| Jun 30, 2023 | 462.70 Mn |
| Mar 31, 2023 | 463.50 Mn |
| Dec 31, 2022 | 468.89 Mn |
| Sep 30, 2022 | 470.00 Mn |
| Jun 30, 2022 | 471.10 Mn |
| Mar 31, 2022 | 472.20 Mn |
| Dec 31, 2021 | 474.35 Mn |
| Sep 30, 2021 | 474.00 Mn |
| Jun 30, 2021 | 474.80 Mn |